Cerity Partners LLC Has $6.20 Million Stock Position in Exelixis, Inc. (NASDAQ:EXEL)

Cerity Partners LLC grew its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 127.3% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 167,915 shares of the biotechnology company's stock after purchasing an additional 94,031 shares during the quarter. Cerity Partners LLC owned approximately 0.06% of Exelixis worth $6,199,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the business. Vanguard Group Inc. boosted its stake in shares of Exelixis by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 29,429,252 shares of the biotechnology company's stock worth $979,994,000 after acquiring an additional 121,750 shares during the period. LSV Asset Management boosted its position in Exelixis by 0.8% in the 4th quarter. LSV Asset Management now owns 8,169,847 shares of the biotechnology company's stock valued at $272,056,000 after buying an additional 67,470 shares during the period. Fuller & Thaler Asset Management Inc. raised its position in Exelixis by 10.2% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 7,630,940 shares of the biotechnology company's stock valued at $254,110,000 after purchasing an additional 708,312 shares in the last quarter. Invesco Ltd. raised its holdings in shares of Exelixis by 308.1% in the fourth quarter. Invesco Ltd. now owns 3,975,241 shares of the biotechnology company's stock valued at $132,376,000 after acquiring an additional 3,001,204 shares in the last quarter. Finally, AQR Capital Management LLC raised its holdings in shares of Exelixis by 25.7% in the 4th quarter. AQR Capital Management LLC now owns 3,967,005 shares of the biotechnology company's stock valued at $132,101,000 after purchasing an additional 810,857 shares in the last quarter. Institutional investors own 85.27% of the company's stock.

Insider Transactions at Exelixis

In other news, CMO Amy C. Peterson sold 72,776 shares of the company's stock in a transaction dated Friday, May 16th. The stock was sold at an average price of $45.47, for a total value of $3,309,124.72. Following the transaction, the chief marketing officer owned 465,393 shares in the company, valued at $21,161,419.71. This represents a 13.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Stelios Papadopoulos sold 36,508 shares of the firm's stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $44.35, for a total transaction of $1,619,129.80. Following the transaction, the director directly owned 1,279,416 shares in the company, valued at approximately $56,742,099.60. The trade was a 2.77% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 458,113 shares of company stock valued at $21,024,817 over the last quarter. Insiders own 2.82% of the company's stock.

Exelixis Stock Up 0.2%

Shares of NASDAQ EXEL traded up $0.09 during trading on Thursday, hitting $44.90. 792,202 shares of the company traded hands, compared to its average volume of 2,946,087. The company has a 50-day moving average price of $42.84 and a 200-day moving average price of $38.25. Exelixis, Inc. has a 1 year low of $22.20 and a 1 year high of $49.62. The firm has a market capitalization of $12.24 billion, a P/E ratio of 20.41, a P/E/G ratio of 0.88 and a beta of 0.28.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Jefferies Financial Group set a $50.00 price objective on shares of Exelixis and gave the stock a "buy" rating in a research report on Tuesday, June 24th. Benchmark reaffirmed a "neutral" rating on shares of Exelixis in a report on Monday, June 23rd. HC Wainwright upped their price target on Exelixis from $47.00 to $53.00 and gave the company a "buy" rating in a research note on Monday, June 30th. Citigroup increased their target price on Exelixis from $45.00 to $56.00 and gave the stock a "buy" rating in a research note on Thursday, May 15th. Finally, Barclays boosted their target price on Exelixis from $29.00 to $40.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 10th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $45.28.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.